Table 4. Effects of policosanol (Reduchole22^®) and orlistat treatment on changes of total cholesterol, HDL cholesterol, and LDL cholesterol in HFD-induced mice model

Groups	Liver lipid profile			Artery lipid profile
	Total cholesterol (ng/mL)2)	HDL cholesterol (ng/mL)	LDL cholesterol (ng/mL)	Total cholesterol (ng/mL)	HDL cholesterol (ng/mL)	LDL cholesterol (ng/mL)
Control (G1)1)	20.13±1.553)***	20.24±0.13***	32.12±0.84***	2.52±0.47***	1.15±0.09***	1.99±0.59***
HFD (G2)	44.75±5.90	8.07±1.45	52.74±0.70	5.19±1.46	0.40±0.08	6.03±0.54
Orlistat (10 mg/kg, G5)	22.50±8.12***	20.34±0.13***	37.13±0.29***	1.74±0.70***	1.22±0.13***	1.83±0.72***
Policosanol (5 mg/kg, G4)	20.95±3.81***	20.19±0.14***	42.77±2.31***	2.20±0.63***	1.17±0.09***	1.72±0.29***
Policosanol (10 mg/kg, G5)	19.53±4.95***	20.46±0.46***	38.93±1.23***	1.89±0.70***	1.28±0.06***	1.69±0.36***
Policosanol (20 mg/kg, G6)	14.78±3.32***	20.25±0.08***	33.34±0.65***	1.71±1.08***	1.27±0.07***	1.60±0.61***

Group 1 (G1), normal control group; Group 2 (G2), HFD-induced group; Group 3 (G3), treated orlistat drug (10 mg/kg) in HFD-induced group; Group 4 (G4), treated policosanol (5 mg/kg) in HFD-induced group; Group 5 (G5), treated policosanol (10 mg/kg) in HFD-induced group; Group 6 (G6), treated policosanol (20 mg/kg) in HFD-induced group.
The cholesterol parameters were measured by using liver and artery in mice.
All values are mean±SD (n=8).
p<0.05,
p<0.01, and
p<0.001 vs. Pathological control (HFD, G2).